Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
Johanna Nilsson1, Johan Gobom1,2, Simon Sjödin1
1Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|May 10, 2021
Summary
Researchers identified novel synaptic protein biomarkers in cerebrospinal fluid for early Alzheimer's disease (AD) detection. These biomarkers reflect synaptic dysfunction, aiding in early diagnosis and prognosis of AD.
Area of Science:
- Neuroscience
- Biochemistry
Background:
- Synaptic dysfunction is an early indicator of Alzheimer's disease (AD) and correlates with cognitive decline.
- There is a critical need for reliable biomarkers to detect synaptic degeneration in AD.
Purpose of the Study:
- To identify and validate novel synaptic proteins in cerebrospinal fluid (CSF) as potential biomarkers for Alzheimer's disease.
- To establish a method for quantifying synaptic proteins to assess synaptic dysfunction.
Main Methods:
- Quantification of 17 synaptic proteins in CSF using solid-phase extraction and parallel reaction monitoring mass spectrometry.
- Analysis of samples from two cross-sectional studies, including AD patients (n=52) and controls (n=37).
Main Results:
- Elevated levels of beta-synuclein, gamma-synuclein, neurogranin, phosphatidylethanolamine-binding protein 1, and 14-3-3 proteins in AD patients compared to controls.
- Decreased concentrations of neuronal pentraxin-2 and neuronal pentraxin receptor in AD patients.
Conclusions:
- A novel method and panel of synaptic proteins have been established as biomarkers for synaptic dysfunction.
- Several identified proteins show potential as synaptic biomarkers for diagnosing Alzheimer's disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
964
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
964
01:21Cerebrospinal Fluid
3.8K
Cerebrospinal fluid (CSF) is a colorless liquid that flows around the brain and the spinal cord, playing a vital role in the protection, support, and overall function of the central nervous system (CNS). CSF production, circulation, and absorption are tightly regulated processes essential for the brain and spinal cord to function properly.
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain....
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain....
3.8K
01:22Alzheimer's Disease: Treatment
471
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
471